Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Abstract Background Although the diagnosis of Alzheimer´s disease (AD) dominates in the tertiary memory clinic setting, there are also patients which show no sign for presence of amyloid in brain when assessed for CSF biomarkers after lumbar puncture (LP) or amyloid PET. Since these amyloid negative (A‐) patients can clinically mimic symptomatic AD patients, it is important to obtain further insight into the in vivo pathology of these patients. This study therefore aimed to perform tau PET imaging with the tracer [18F]RO948 and measure plasma biomarkers in patients clinically diagnosed as primary age‐related tauopathy (PART) and limbic dominant TDP‐43 age‐related encephalopathy (LATE) at the clinic for cognitive disorders at Karolinska University Hospital. Method Four patients diagnosed with PART (mean age 76 years) and four with LATE (mean age 79 years) were included in the study. Clinical characteristics and biomarkers are reported in Table 1. The ATN classification for PART patients was A‐T+N+ and for LATE patients A‐T‐N+. On the same day, all participants underwent [18F]RO948 tau PET and MRI scans, and blood sampling for plasma biomarker analysis using the NuLISAseq (Alamarbio) CNS panel. The obtained data was compared with 27 amyloid positive MCI and AD patients from Karolinska as well as 10 cognitive healthy controls. Result Low uptake of [18F]RO948 was observed in PART and LATE brains compared to MCI A+ as shown in Figure 1, including also Radar plots of different brain regions. Box plot data (Figure 2) showed low [18F]RO948 regional uptake except for a higher uptake ( p <0.05) in the putamen in PART and LATE compared to controls. Higher plasma levels of ptau217, ptau181, ptau231 were observed in PART patients ( p <0.05) but not in LATE compared to cognitively healthy controls. Plasma ptau217 levels were however higher in LOAD ( p <0.05) compared to PART. Higher plasma Aß42 values were observed both in LATE and PART compared to LOAD. Conclusion PART and LATE patients exhibit Tau PET uptake similar to that of controls, except in the putamen. Additionally, PART patients show elevated plasma levels of p ‐tau 217, p ‐tau 181, and p ‐tau 231, whereas LATE patients do not.

What this study adds

Evidence grade: Low

In four PART and four LATE patients, [18F]RO948 tau-PET showed low uptake compared with amyloid-positive MCI patients, with higher putamen uptake than controls. The very small sample size makes this preliminary, and it addresses diagnosis and in vivo pathology rather than treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Nordberg, A. K., Bucci, M. B., Zapater‐Fajarí, M., Chiotis, K., Wall, A. E., Eriksson, J., et al. (2025). [18F] RO948 Tau PET imaging and plasma biomarkers in PART and LATE patients compared with sporadic Alzheimer's Disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_107395

Vancouver

Nordberg AK, Bucci MB, Zapater‐Fajarí M, Chiotis K, Wall AE, Eriksson J, et al. [18F] RO948 Tau PET imaging and plasma biomarkers in PART and LATE patients compared with sporadic Alzheimer's Disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_107395.

BibTeX

@article{nordberg2025-1419fb90,
  author  = {Nordberg, Agneta K. and Bucci, Marco Brady and Zapater‐Fajarí, Mariola and Chiotis, Konstantinos and Wall, Anders E. and Eriksson, Jonas and Antoni, Gunnar and Pola, Ilaria and others},
  title   = {{[18F] RO948 Tau PET imaging and plasma biomarkers in PART and LATE patients compared with sporadic Alzheimer's Disease}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_107395},
  url     = {https://doi.org/10.1002/alz70856_107395}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In four PART and four LATE patients, [18F]RO948 tau-PET showed low uptake compared with amyloid-positive MCI patients, with higher putamen uptake than controls. The very small sample size makes this preliminary, and it addresses diagnosis and in vivo pathology rather than treatment or cure.

Study details

How this study scored 35/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 35 of 100.35 of 100 points earned65 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Nenad Bogdanović: h-index 65 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 14 institution(s) in 4 countries
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 35 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Brain scans and imaging from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →